205 related articles for article (PubMed ID: 35536124)
1. In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
Med Lett Drugs Ther; 2022 May; 64(1650):79. PubMed ID: 35536124
[No Abstract] [Full Text] [Related]
2. In brief: GI effects of GLP-1 receptor agonists.
Med Lett Drugs Ther; 2023 Nov; 65(1690):191-192. PubMed ID: 37983121
[No Abstract] [Full Text] [Related]
3. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
4. Tirzepatide (Mounjaro) for type 2 diabetes.
Med Lett Drugs Ther; 2022 Jul; 64(1654):105-107. PubMed ID: 35802842
[No Abstract] [Full Text] [Related]
5. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
[No Abstract] [Full Text] [Related]
6. Semaglutide: a new drug for the treatment of obesity.
Lexchin J; Mintzes B
Drug Ther Bull; 2023 Nov; 61(12):182-188. PubMed ID: 37879878
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract][Full Text] [Related]
8. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
9. A new indication for semaglutide (Wegovy).
Med Lett Drugs Ther; 2024 Apr; 66(1701):66-67. PubMed ID: 38691645
[No Abstract] [Full Text] [Related]
10. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
11. Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
Karásek D
Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
[TBL] [Abstract][Full Text] [Related]
12. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
Scheen AJ
Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
[No Abstract] [Full Text] [Related]
13. The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.
Dichtel LE
Hepatology; 2021 Oct; 74(4):2290-2292. PubMed ID: 33960005
[No Abstract] [Full Text] [Related]
14. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
Hall S; Isaacs D; Clements JN
Clin Pharmacokinet; 2018 Dec; 57(12):1529-1538. PubMed ID: 29915923
[TBL] [Abstract][Full Text] [Related]
17. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
19. In brief: Semaglutide (Wegovy) for weight loss in children.
Med Lett Drugs Ther; 2023 Feb; 65(1670):31-32. PubMed ID: 36757837
[No Abstract] [Full Text] [Related]
20. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
